Neuphoria Therapeutics Inc. Common Stock (NEUP)
Stock · NASDAQ · Health Care
$3.31as of 10/16/2026
Price chart
Active signals
NEUP Signal Track Record
How signals performed across all stocks →What NEUP's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume SpikeActive now | 35 | -3.4% | 40% | August 21, 2026 |
| Bollinger Band Breakdown | 22 | +0.4% | 50% | September 24, 2026 |
| Bollinger Band Breakout | 21 | -10.7% | 29% | March 4, 2026 |
| 200-Day Moving Average TouchActive now | 4 | +8.5% | 50% | May 19, 2025 |
| Any 20-session window (baseline) | -3.4% | 41% |
Computed by MarketWall from daily closing prices since October 3, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About NEUP
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 pos…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 1
- Website
- www.neuphoriatx.com/
Fundamentals
- 1-day range
- $3.33$3.41
- Market cap
- $21.08M
- P/E (trailing)
- —
- P/E (forward)
- -1.36
- EPS (trailing)
- $-5.00
- Dividend yield
- —
- Beta
- 0.76
- Avg. volume
- 161.4K
How Neuphoria Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2026 annual results
Source: 10-K filed Sep 18, 2026 · via SEC EDGAR / Finnhub
Neuphoria Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- NEUPNeuphoria Therapeutics Inc. Common Stock$3.3▼ 0.30%Market cap $21.08MP/E —$3.19$17.9
- ATOSAtossa Therapeutics Inc. Common Stock$2.91▲ 9.81%Market cap $20.84MP/E —$1.7$16.5
- QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares$2.47▼ 8.86%Market cap $20.67MP/E —$2.85$23.1
- ALLRAllarity Therapeutics Inc. Common Stock$0.895▲ 7.44%Market cap $21.65MP/E —$0.769$1.84
- CALCCalciMedica Inc. Common Stock$1.04▼ 3.70%Market cap $21.88MP/E —$1.27$36
- NXTCNextCure Inc. Common Stock$6.24▼ 9.30%Market cap $20.19MP/E —$1.55$15.74
- CLRBCellectar Biosciences Inc. Common Stock$1.14▼ 4.20%Market cap $20.14MP/E —$1.15$5.07
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NEUP Neuphoria Therapeutics Inc. Common Stock | $21.08M | — | $3.3 | ▼ 0.30% | $3.19$17.9 |
| ATOS Atossa Therapeutics Inc. Common Stock | $20.84M | — | $2.91 | ▲ 9.81% | $1.7$16.5 |
| QNTM Quantum Biopharma Ltd. Class B Subordinate Voting Shares | $20.67M | — | $2.47 | ▼ 8.86% | $2.85$23.1 |
| ALLR Allarity Therapeutics Inc. Common Stock | $21.65M | — | $0.895 | ▲ 7.44% | $0.769$1.84 |
| CALC CalciMedica Inc. Common Stock | $21.88M | — | $1.04 | ▼ 3.70% | $1.27$36 |
| NXTC NextCure Inc. Common Stock | $20.19M | — | $6.24 | ▼ 9.30% | $1.55$15.74 |
| CLRB Cellectar Biosciences Inc. Common Stock | $20.14M | — | $1.14 | ▼ 4.20% | $1.15$5.07 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Scancell revs up for Nasdaq listing as cancer vaccine developer prepares phase III melanoma trialYahoo · 10/9/2026
- Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 developmentYahoo · 9/24/2026
- Accenture, Abivax and 3 Stocks to Watch Heading Into MondayBenzinga · 9/21/2026
- Neuphoria Therapeutics Q4 EPS $(0.95) Misses $(0.56) Estimate, Sales $1.174M.Benzinga · 9/18/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 1.66M
- Total value held
- $6.60M
- Institutional holders
- 18
- Unknown875.3K
- Unknown155.4K
- Unknown151.0K
- Unknown142.2K
- Unknown76.7K
- Unknown52.0K
- Unknown47.4K
- Unknown33.6K
- Unknown30.0K
- Unknown26.5K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Scancell Secures Debt Financing for Phase 3 Trials
Scancell, a subsidiary of Neuphoria Therapeutics, has completed up to US$25 million in debt financing. This funding provides additional options to support the Phase 3 development of iSCIB1+. The capital helps finance clinical trials, which is a key step in the company's development pipeline.
Scancell Secures Debt Financing for Phase 3 Trials. Scancell, a subsidiary of Neuphoria Therapeutics, has completed up to US$25 million in debt financing. This funding provides additional options to support the Phase 3 development of iSCIB1+. The capital helps finance clinical trials, which is a key step in the company's development pipeline.